Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea

Nayoung Kim, Soo Heon Park, Geom Seog Seo, Sang Woo Lee, Jae Woo Kim, Kwang Jae Lee, Won Chang Shin, Tae Nyeun Kim, Moo In Park, Jong Jae Park, Su Jin Hong, Ki Nam Shim, Sang Wook Kim, Yong Woon Shin, Young Woon Chang, Hoon-Jai Chun, Ok Jae Lee, Won Joong Jeon, Chan Guk Park, Chang Min ChoCheol Hee Park, Sun Young Won, Gin Hyug Lee, Kyung Sik Park, Jeong Eun Shin, Heung Up Kim, Joon Yong Park, Hiun Suk Chae, Geun Am Song, Jae Gyu Kim, Byung Chul Yoon, Sangyong Seol, Hyun Chae Jung, In Sik Chung

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background and Aims: Lafutidine is a novel H2-receptor antagonist with gastroprotective activity that includes enhancement of gastric mucosal blood flow. The aim of the present study was to test the efficacy of 7- or 14-day lafutidine-clarithromycin-amoxicillin therapy versus a lansoprazole-based regimen for Helicobacter pylori eradication. Methods: Four hundred and sixty-three patients with H. pylori-infected peptic ulcer disease were randomized to one of four regimens: (1) lafutidine (20 mg b.i.d.), clarithromycin (500 mg b.i.d.) and amoxicillin (1000 mg b.i.d.) for 7 days (the 7LFT group) or (2) for 14 days (the 14LFT group); (3) lansoprazole (30 mg b.i.d.), clarithromycin (500 mg b.i.d.), and amoxicillin (1000 mg b.i.d.) for 7 days (the 7LPZ group); or (4) for 14 days (the 14LPZ group). The eradication rates, drug compliance, and adverse effects among the four regimens were compared. Results: The eradication rates by the intention-to-treat and per-protocol analyses in the 7LFT and 7LPZ groups were 76.5% and 81.6%, and 76.9% and 82.0% (p =.94 and.95), respectively. The eradication rates by intention-to-treat and per-protocol analyses in the 14LFT and 14LPZ groups were 78.2% and 82.2%, and 80.4% and 85.9% (p =.70 and.49), respectively. The treatment duration for 7 days or 14 days did not affect the eradication rates. In addition, the adverse effect rates and discontinuation rates were similar among the four groups. Furthermore, the ulcer cure rate and symptom response rate were similar in the lafutidine and lansoprazole groups. Conclusion: The results of this study showed that lafutidine-clarithromycin-amoxicillin therapy was a safe and effective as lansoprazole-based triple therapy for the eradication rate of H. pylori, and could be considered as an additional treatment option.

Original languageEnglish
Pages (from-to)542-549
Number of pages8
JournalHelicobacter
Volume13
Issue number6
DOIs
Publication statusPublished - 2008 Dec 1

Fingerprint

Lansoprazole
Clarithromycin
Amoxicillin
Korea
Helicobacter pylori
Histamine H2 Receptors
Therapeutics
Peptic Ulcer
Ulcer
Stomach
lafutidine
Pharmaceutical Preparations

Keywords

  • Eradication
  • Helicobacter pylori
  • Lafutidine
  • Triple therapy

ASJC Scopus subject areas

  • Gastroenterology
  • Infectious Diseases

Cite this

Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea. / Kim, Nayoung; Park, Soo Heon; Seo, Geom Seog; Lee, Sang Woo; Kim, Jae Woo; Lee, Kwang Jae; Shin, Won Chang; Kim, Tae Nyeun; Park, Moo In; Park, Jong Jae; Hong, Su Jin; Shim, Ki Nam; Kim, Sang Wook; Shin, Yong Woon; Chang, Young Woon; Chun, Hoon-Jai; Lee, Ok Jae; Jeon, Won Joong; Park, Chan Guk; Cho, Chang Min; Park, Cheol Hee; Won, Sun Young; Lee, Gin Hyug; Park, Kyung Sik; Shin, Jeong Eun; Kim, Heung Up; Park, Joon Yong; Chae, Hiun Suk; Song, Geun Am; Kim, Jae Gyu; Yoon, Byung Chul; Seol, Sangyong; Jung, Hyun Chae; Chung, In Sik.

In: Helicobacter, Vol. 13, No. 6, 01.12.2008, p. 542-549.

Research output: Contribution to journalArticle

Kim, N, Park, SH, Seo, GS, Lee, SW, Kim, JW, Lee, KJ, Shin, WC, Kim, TN, Park, MI, Park, JJ, Hong, SJ, Shim, KN, Kim, SW, Shin, YW, Chang, YW, Chun, H-J, Lee, OJ, Jeon, WJ, Park, CG, Cho, CM, Park, CH, Won, SY, Lee, GH, Park, KS, Shin, JE, Kim, HU, Park, JY, Chae, HS, Song, GA, Kim, JG, Yoon, BC, Seol, S, Jung, HC & Chung, IS 2008, 'Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea', Helicobacter, vol. 13, no. 6, pp. 542-549. https://doi.org/10.1111/j.1523-5378.2008.00648.x
Kim, Nayoung ; Park, Soo Heon ; Seo, Geom Seog ; Lee, Sang Woo ; Kim, Jae Woo ; Lee, Kwang Jae ; Shin, Won Chang ; Kim, Tae Nyeun ; Park, Moo In ; Park, Jong Jae ; Hong, Su Jin ; Shim, Ki Nam ; Kim, Sang Wook ; Shin, Yong Woon ; Chang, Young Woon ; Chun, Hoon-Jai ; Lee, Ok Jae ; Jeon, Won Joong ; Park, Chan Guk ; Cho, Chang Min ; Park, Cheol Hee ; Won, Sun Young ; Lee, Gin Hyug ; Park, Kyung Sik ; Shin, Jeong Eun ; Kim, Heung Up ; Park, Joon Yong ; Chae, Hiun Suk ; Song, Geun Am ; Kim, Jae Gyu ; Yoon, Byung Chul ; Seol, Sangyong ; Jung, Hyun Chae ; Chung, In Sik. / Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea. In: Helicobacter. 2008 ; Vol. 13, No. 6. pp. 542-549.
@article{9d97ff00806948aeb95d42db98a3d7f1,
title = "Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea",
abstract = "Background and Aims: Lafutidine is a novel H2-receptor antagonist with gastroprotective activity that includes enhancement of gastric mucosal blood flow. The aim of the present study was to test the efficacy of 7- or 14-day lafutidine-clarithromycin-amoxicillin therapy versus a lansoprazole-based regimen for Helicobacter pylori eradication. Methods: Four hundred and sixty-three patients with H. pylori-infected peptic ulcer disease were randomized to one of four regimens: (1) lafutidine (20 mg b.i.d.), clarithromycin (500 mg b.i.d.) and amoxicillin (1000 mg b.i.d.) for 7 days (the 7LFT group) or (2) for 14 days (the 14LFT group); (3) lansoprazole (30 mg b.i.d.), clarithromycin (500 mg b.i.d.), and amoxicillin (1000 mg b.i.d.) for 7 days (the 7LPZ group); or (4) for 14 days (the 14LPZ group). The eradication rates, drug compliance, and adverse effects among the four regimens were compared. Results: The eradication rates by the intention-to-treat and per-protocol analyses in the 7LFT and 7LPZ groups were 76.5{\%} and 81.6{\%}, and 76.9{\%} and 82.0{\%} (p =.94 and.95), respectively. The eradication rates by intention-to-treat and per-protocol analyses in the 14LFT and 14LPZ groups were 78.2{\%} and 82.2{\%}, and 80.4{\%} and 85.9{\%} (p =.70 and.49), respectively. The treatment duration for 7 days or 14 days did not affect the eradication rates. In addition, the adverse effect rates and discontinuation rates were similar among the four groups. Furthermore, the ulcer cure rate and symptom response rate were similar in the lafutidine and lansoprazole groups. Conclusion: The results of this study showed that lafutidine-clarithromycin-amoxicillin therapy was a safe and effective as lansoprazole-based triple therapy for the eradication rate of H. pylori, and could be considered as an additional treatment option.",
keywords = "Eradication, Helicobacter pylori, Lafutidine, Triple therapy",
author = "Nayoung Kim and Park, {Soo Heon} and Seo, {Geom Seog} and Lee, {Sang Woo} and Kim, {Jae Woo} and Lee, {Kwang Jae} and Shin, {Won Chang} and Kim, {Tae Nyeun} and Park, {Moo In} and Park, {Jong Jae} and Hong, {Su Jin} and Shim, {Ki Nam} and Kim, {Sang Wook} and Shin, {Yong Woon} and Chang, {Young Woon} and Hoon-Jai Chun and Lee, {Ok Jae} and Jeon, {Won Joong} and Park, {Chan Guk} and Cho, {Chang Min} and Park, {Cheol Hee} and Won, {Sun Young} and Lee, {Gin Hyug} and Park, {Kyung Sik} and Shin, {Jeong Eun} and Kim, {Heung Up} and Park, {Joon Yong} and Chae, {Hiun Suk} and Song, {Geun Am} and Kim, {Jae Gyu} and Yoon, {Byung Chul} and Sangyong Seol and Jung, {Hyun Chae} and Chung, {In Sik}",
year = "2008",
month = "12",
day = "1",
doi = "10.1111/j.1523-5378.2008.00648.x",
language = "English",
volume = "13",
pages = "542--549",
journal = "Helicobacter",
issn = "1083-4389",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea

AU - Kim, Nayoung

AU - Park, Soo Heon

AU - Seo, Geom Seog

AU - Lee, Sang Woo

AU - Kim, Jae Woo

AU - Lee, Kwang Jae

AU - Shin, Won Chang

AU - Kim, Tae Nyeun

AU - Park, Moo In

AU - Park, Jong Jae

AU - Hong, Su Jin

AU - Shim, Ki Nam

AU - Kim, Sang Wook

AU - Shin, Yong Woon

AU - Chang, Young Woon

AU - Chun, Hoon-Jai

AU - Lee, Ok Jae

AU - Jeon, Won Joong

AU - Park, Chan Guk

AU - Cho, Chang Min

AU - Park, Cheol Hee

AU - Won, Sun Young

AU - Lee, Gin Hyug

AU - Park, Kyung Sik

AU - Shin, Jeong Eun

AU - Kim, Heung Up

AU - Park, Joon Yong

AU - Chae, Hiun Suk

AU - Song, Geun Am

AU - Kim, Jae Gyu

AU - Yoon, Byung Chul

AU - Seol, Sangyong

AU - Jung, Hyun Chae

AU - Chung, In Sik

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Background and Aims: Lafutidine is a novel H2-receptor antagonist with gastroprotective activity that includes enhancement of gastric mucosal blood flow. The aim of the present study was to test the efficacy of 7- or 14-day lafutidine-clarithromycin-amoxicillin therapy versus a lansoprazole-based regimen for Helicobacter pylori eradication. Methods: Four hundred and sixty-three patients with H. pylori-infected peptic ulcer disease were randomized to one of four regimens: (1) lafutidine (20 mg b.i.d.), clarithromycin (500 mg b.i.d.) and amoxicillin (1000 mg b.i.d.) for 7 days (the 7LFT group) or (2) for 14 days (the 14LFT group); (3) lansoprazole (30 mg b.i.d.), clarithromycin (500 mg b.i.d.), and amoxicillin (1000 mg b.i.d.) for 7 days (the 7LPZ group); or (4) for 14 days (the 14LPZ group). The eradication rates, drug compliance, and adverse effects among the four regimens were compared. Results: The eradication rates by the intention-to-treat and per-protocol analyses in the 7LFT and 7LPZ groups were 76.5% and 81.6%, and 76.9% and 82.0% (p =.94 and.95), respectively. The eradication rates by intention-to-treat and per-protocol analyses in the 14LFT and 14LPZ groups were 78.2% and 82.2%, and 80.4% and 85.9% (p =.70 and.49), respectively. The treatment duration for 7 days or 14 days did not affect the eradication rates. In addition, the adverse effect rates and discontinuation rates were similar among the four groups. Furthermore, the ulcer cure rate and symptom response rate were similar in the lafutidine and lansoprazole groups. Conclusion: The results of this study showed that lafutidine-clarithromycin-amoxicillin therapy was a safe and effective as lansoprazole-based triple therapy for the eradication rate of H. pylori, and could be considered as an additional treatment option.

AB - Background and Aims: Lafutidine is a novel H2-receptor antagonist with gastroprotective activity that includes enhancement of gastric mucosal blood flow. The aim of the present study was to test the efficacy of 7- or 14-day lafutidine-clarithromycin-amoxicillin therapy versus a lansoprazole-based regimen for Helicobacter pylori eradication. Methods: Four hundred and sixty-three patients with H. pylori-infected peptic ulcer disease were randomized to one of four regimens: (1) lafutidine (20 mg b.i.d.), clarithromycin (500 mg b.i.d.) and amoxicillin (1000 mg b.i.d.) for 7 days (the 7LFT group) or (2) for 14 days (the 14LFT group); (3) lansoprazole (30 mg b.i.d.), clarithromycin (500 mg b.i.d.), and amoxicillin (1000 mg b.i.d.) for 7 days (the 7LPZ group); or (4) for 14 days (the 14LPZ group). The eradication rates, drug compliance, and adverse effects among the four regimens were compared. Results: The eradication rates by the intention-to-treat and per-protocol analyses in the 7LFT and 7LPZ groups were 76.5% and 81.6%, and 76.9% and 82.0% (p =.94 and.95), respectively. The eradication rates by intention-to-treat and per-protocol analyses in the 14LFT and 14LPZ groups were 78.2% and 82.2%, and 80.4% and 85.9% (p =.70 and.49), respectively. The treatment duration for 7 days or 14 days did not affect the eradication rates. In addition, the adverse effect rates and discontinuation rates were similar among the four groups. Furthermore, the ulcer cure rate and symptom response rate were similar in the lafutidine and lansoprazole groups. Conclusion: The results of this study showed that lafutidine-clarithromycin-amoxicillin therapy was a safe and effective as lansoprazole-based triple therapy for the eradication rate of H. pylori, and could be considered as an additional treatment option.

KW - Eradication

KW - Helicobacter pylori

KW - Lafutidine

KW - Triple therapy

UR - http://www.scopus.com/inward/record.url?scp=55949130872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55949130872&partnerID=8YFLogxK

U2 - 10.1111/j.1523-5378.2008.00648.x

DO - 10.1111/j.1523-5378.2008.00648.x

M3 - Article

C2 - 19166420

AN - SCOPUS:55949130872

VL - 13

SP - 542

EP - 549

JO - Helicobacter

JF - Helicobacter

SN - 1083-4389

IS - 6

ER -